

Mark T Drayson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3127404/publications.pdf>

Version: 2024-02-01

11
papers

317
citations

1163117
8
h-index

1281871
11
g-index

11
all docs

11
docs citations

11
times ranked

570
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. <i>Blood</i> , 2006, 108, 2013-2019.	1.4	88
2	Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease. <i>PLoS ONE</i> , 2013, 8, e56422.	2.5	56
3	Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. <i>Leukemia</i> , 2018, 32, 1727-1738.	7.2	50
4	Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. <i>British Journal of Haematology</i> , 2017, 178, 220-230.	2.5	34
5	Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. <i>BMC Nephrology</i> , 2018, 19, 178.	1.8	24
6	Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. <i>Leukemia</i> , 2021, 35, 2043-2053.	7.2	23
7	Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic <sc>B</sc>urkitt lymphoma in <sc>M</sc>alawi; an open-label, single-arm, phase 2 study (ISRCTN34303497). <i>British Journal of Haematology</i> , 2014, 164, 888-890.	2.5	13
8	Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test. <i>BMC Nephrology</i> , 2017, 18, 247.	1.8	12
9	Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management. <i>Blood Cancer Journal</i> , 2020, 10, 114.	6.2	8
10	Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. <i>Lancet Haematology</i> , 2017, 4, e584-e594.	4.6	6
11	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-94.	2.8	3